<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Potassium bicarbonate and potassium citrate (effervescent): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Potassium bicarbonate and potassium citrate (effervescent): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Potassium bicarbonate and potassium citrate (effervescent): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11516" href="/d/html/11516.html" rel="external">see "Potassium bicarbonate and potassium citrate (effervescent): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F211765"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Effer-K;</li>
<li>K-Prime;</li>
<li>Klor-Con/EF</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F211778"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Electrolyte Supplement, Oral</li></ul></div>
<div class="block doa drugH1Div" id="F211767"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="04b25be2-c11a-453b-bd96-7677d7805c9b">Hypokalemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia (mild to moderate), treatment (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Doses are expressed as mEq of potassium (1 mEq = 1 mmol potassium). Typically, potassium <i>chloride</i> is preferred because it corrects serum potassium more quickly than other salts and hypochloremia may develop with potassium citrate use (Asmar 2012; Cohn 2000). Consider use in patients with hypokalemia accompanied by metabolic acidosis (eg, due to diarrhea or renal tubular acidosis). Individualize dosing based on serum potassium levels and clinical factors (eg, underlying cause, presence of symptoms, concomitant medications, ongoing potassium losses). Concurrent hypomagnesemia requires correction to facilitate potassium repletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31706619','lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31706619','lexi-content-ref-16085929'])">Ref</a></span>). General guidance is provided below; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to moderate (serum potassium 3 to 3.4 mEq/L): Oral:</b> Initial: 10 to 20 mEq 2 to 4 times daily; base subsequent dosing on electrolyte monitoring (eg, serum potassium, sodium, chloride, carbon dioxide concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>)) and clinical factors; limit single doses to 20 to 25 mEq/dose to avoid GI discomfort (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22901631','lexi-content-ref-10979053','lexi-content-ref-16085929','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22901631','lexi-content-ref-10979053','lexi-content-ref-16085929','lexi-content-ref-Mount.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991953"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, patients with chronic kidney disease require serum potassium monitoring and appropriate dosage adjustment.</p></div>
<div class="block doha drugH1Div" id="F50989248"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F211768"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F211745"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hyperkalemia</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting</p></div>
<div class="block coi drugH1Div" id="F211759"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hyperkalemia. <b>Note:</b> The manufacturer's labeling also states that concomitant use of potassium-sparing diuretics is contraindicated. While this combination should generally be avoided, in select patients under close medical supervision, combined use of potassium supplements and potassium-sparing diuretics may be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F211742"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Metabolic acidosis: Patients with hypokalemia accompanied by metabolic acidosis should be treated with an alkalinizing potassium salt.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (eg, untreated Addison's disease, heat cramps, severe tissue breakdown from trauma or burns).</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Avoid with severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACE inhibitors, potassium-sparing diuretics, potassium-containing salt substitutes).</p></div>
<div class="block dosfc drugH1Div" id="F26930718"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Each tablet contains 10, 20, or 25 mEq potassium and delivers approximately 10, 20 or 25 mEq bicarbonate.</p></div>
<div class="block foc drugH1Div" id="F211754"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Effervescent, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 10 mEq</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 10 mEq [contains fd&amp;c red #40 (allura red ac dye); cherry-vanilla flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 20 mEq [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 20 mEq [scored; contains fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow); orange cream flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 25 mEq [lime flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 25 mEq [contains fd&amp;c red #40 (allura red ac dye), fd&amp;c red #40(allura red ac)aluminum lake, saccharin; cherry berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 25 mEq [contains fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6(sunset yellow)alumin lake, saccharin; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 25 mEq [contains quinoline (d&amp;c yellow #10) aluminum lake, quinoline yellow (d&amp;c yellow #10), saccharin; lemon citrus flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effer-K: 25 mEq [contains saccharin; unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">K-Prime: 25 mEq [contains fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6(sunset yellow)alumin lake, saccharin; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con/EF: 25 mEq [contains fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6(sunset yellow)alumin lake, saccharin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con/EF: 25 mEq [DSC] [sugar free; contains fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6(sunset yellow)alumin lake, saccharin; orange flavor]</p></div>
<div class="block geq drugH1Div" id="F211738"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F211760"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, effervescent</b> (Effer-K Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq (per each): $0.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq (per each): $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mEq (per each): $0.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, effervescent</b> (K-Prime Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mEq (per each): $0.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, effervescent</b> (Klor-Con/EF Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mEq (per each): $1.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F16040805"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Do not remove tablet from pouch until ready to use. Completely dissolve tablet in 4 ounces (115 mL) of water. Administer with meals and sip slowly over 5 to 10 minutes.</p></div>
<div class="block use drugH1Div" id="F211756"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypokalemia, treatment</b>: Treatment of hypokalemia, particularly when it is necessary to avoid chloride or the acid/base status requires bicarbonate.</p></div>
<div class="block mst drugH1Div" id="F211785"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Klor-Con may be confused with Klaron</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299915"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F211747"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Antacids may decrease the serum concentration of Acalabrutinib.  Management: Separate administration of acalabrutinib capsules from the administration of any antacid by at least 2 hours in order to minimize the potential for a significant interaction. Acalabrutinib tablets are not expected to interact with antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AMILoride: Potassium Salts may enhance the hyperkalemic effect of AMILoride.  Management: Amiloride and potassium supplements should not be used except in severe or refractory cases of hypokalemia. If coadministered, monitor serum potassium closely as rapid increases in potassium are possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.  Management: Consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Citrate. Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Antacids may decrease the absorption of Atazanavir.  Management: Administer antacids 1 to 2 hours before or 2 hours after atazanavir to minimize the risk of a clinically significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Antacids may decrease the serum concentration of Belumosudil.  Management: Consider separating administration of belumosudil and antacids by 2 hours and monitor for reduced belumosudil efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.  Management: Antacids should not be used within 1 hour before bisacodyl administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subcitrate: Antacids may diminish the therapeutic effect of Bismuth Subcitrate.  Management: Avoid administration of antacids within 30 minutes of bismuth subcitrate (tripotassium bismuth dicitrate) administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Captopril: Antacids may decrease the serum concentration of Captopril. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Antacids may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate the administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Antacids may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Antacids may decrease the serum concentration of Dasatinib.  Management: Simultaneous administration of dasatinib and antacids should be avoided. Administer antacids 2 hours before or 2 hours after dasatinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: Antacids may decrease the absorption of Diacerein. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Potassium supplements may be needed to treat/prevent hypokalemia in select patients with heart failure receiving eplerenone and high dose loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium Salts may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Alkalinizing Agents may decrease the excretion of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosinopril: Antacids may decrease the serum concentration of Fosinopril.  Management: The US and Canadian fosinopril manufacturer labels recommend separating the doses of antacids and fosinopril by 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Antacids may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or 6 hours after administration of an antacid, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Antacids may decrease serum concentrations of the active metabolite(s) of Infigratinib. Antacids may decrease the serum concentration of Infigratinib.  Management: Avoid coadministration of infigratinib with antacids or other gastric acid-lowering agents. If antacids cannot be avoided, administer infigratinib 2 hours before or after administration of antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: Antacids may decrease the absorption of Iron Preparations.  Management: No action is likely necessary for the majority of patients who only use antacids intermittently or occasionally. Consider separating doses of oral iron and antacids in patients who require chronic use of both agents and monitor for reduced iron efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Antacids may decrease the absorption of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Antacids may decrease the serum concentration of Itraconazole. Antacids may increase the serum concentration of Itraconazole.  Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any antacids. Exposure to Tolsura brand itraconazole may be increased by antacids; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer antacids at least 1 hour prior to, or 2 hours after, ketoconazole. Additionally, administer ketoconazole with an acidic beverage (eg, non-diet cola) and monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: Antacids may diminish the therapeutic effect of Lanthanum.  Management: Administer antacid products at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir.  Management: Separate the administration of ledipasvir and antacids by 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Antacids may decrease the absorption of Levoketoconazole.  Management: Advise patients to take antacids at least 2 hours after taking levoketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Antacids may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with the Apriso brand of mesalamine extended-release capsules. The optimal duration of dose separation is unknown. Other mesalamine products do not contain this interaction warning.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: Antacids may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding the concomitant use of medications that alkalinize the urine, such as antacids, and methenamine. Monitor for decreased therapeutic effects of methenamine if used concomitant with antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamins and antacids by as much time as possible to minimize impact of this interaction. Monitor for decreased therapeutic efficacy of oral iron preparations during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Antacids may decrease the serum concentration of Neratinib. Specifically, antacids may reduce neratinib absorption.  Management: Separate the administration of neratinib and antacids by giving neratinib at least 3 hours after the antacid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Antacids may decrease the serum concentration of Nirogacestat.  Management: If acid-reducing therapy is required, separate nirogacestat administration from antacids by 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Antacids may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Antacids may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of antacids in combination with pazopanib whenever possible. Separate doses by several hours if antacid treatment is considered necessary. The impact of dose separation has not been investigated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Antacids may decrease the serum concentration of Pexidartinib.  Management: Administer pexidartinib at least 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate administration. Separating administration of oral phosphate supplements from antacid administration by as long as possible may minimize the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Phosphate: Antacids may decrease the serum concentration of Potassium Phosphate.  Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after oral rilpivirine when used with most rilpivirine products. However, administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Antacids may decrease the serum concentration of Riociguat.  Management: Separate the administration of antacids and riociguat by at least 1 hour in order to minimize any potential interaction. Monitor clinical response to riociguat more closely in patients using this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Antacids may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Antacids may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and antacids should be avoided. If coadministration cannot be avoided, selpercatinib should be administered 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. Specifically, the risk of  metabolic alkalosis may be increased. Antacids may diminish the therapeutic effect of Sodium Polystyrene Sulfonate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotalol: Antacids may decrease the serum concentration of Sotalol.  Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Antacids may decrease the serum concentration of Sotorasib.  Management: Avoid coadministration of sotorasib and antacids. If use of a gastric acid suppressing medication cannot be avoided, administer sotorasib 4 hours before or 10 hours after oral antacid administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Antacids may decrease the serum concentration of Sparsentan.  Management: Administer sparsentan 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Potassium Salts may enhance the hyperkalemic effect of Spironolactone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: Antacids may diminish the therapeutic effect of Sucralfate.  Management: Consider separating the administration of antacids and sucralfate by at least 30 minutes.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antacids may decrease the serum concentration of Sulpiride.  Management: Separate administration of antacids and sulpiride by at least 2 hours in order to minimize the impact of antacids on sulpiride absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Antacids may decrease the absorption of Tetracyclines.  Management: Separate administration of antacids and oral tetracycline derivatives by several hours when possible to minimize the extent of this potential interaction. Monitor for decreased therapeutic effects of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Antacids may decrease the absorption of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamterene: Potassium Salts may enhance the hyperkalemic effect of Triamterene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Antacids may decrease the serum concentration of Velpatasvir.  Management: Separate administration of velpatasvir and antacids by at least 4 hours.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F14287300"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted with this combination. See individual agents.</p></div>
<div class="block brc drugH1Div" id="F14287301"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block dic drugH1Div" id="F51341141"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Dietary adequate intake (AI) (IOM 2004): Healthy adults: 120 mEq/day (4.7 g/day)</p></div>
<div class="block mop drugH1Div" id="F211752"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Electrolytes (including serum potassium, chloride, magnesium, and bicarbonate); kidney function; cardiac function</p></div>
<div class="block rer drugH1Div" id="F13203078"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Reference ranges may vary depending on the laboratory</p>
<p style="text-indent:-2em;margin-left:2em;">Serum potassium: 3.5 to 5.2 mEq/L</p></div>
<div class="block pha drugH1Div" id="F211741"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Potassium is needed for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function</p></div>
<div class="block phk drugH1Div" id="F211758"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed from upper GI tract </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Enters cells via active transport from extracellular fluid </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58196207"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Kalium Hausmann | Kalium Hausmann Effervettes</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">K</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Kalinor | Pot K</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22901631">
<a name="22901631"></a>Asmar A, Mohandas R, Wingo CS. A physiologic-based approach to the treatment of a patient with hypokalemia. <i>Am J Kidney Dis</i>. 2012;60(3):492-497. doi:10.1053/j.ajkd.2012.01.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/22901631/pubmed" id="22901631" target="_blank">22901631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10979053">
<a name="10979053"></a>Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. <i>Arch Intern Med</i>. 2000;160(16):2429-2436. doi:10.1001/archinte.160.16.2429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/10979053/pubmed" id="10979053" target="_blank">10979053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nomax.1">
<a name="Nomax.1"></a>Effer-K 10 and 20 mEq (effervescent potassium bicarbonate/citric acid) [prescribing information]. St. Louis, MO: Nomax Inc; April 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/Nomax.1/pubmed" id="Nomax.1" target="_blank">Nomax.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nomax.2">
<a name="Nomax.2"></a>Effer-K 25 mEq (effervescent potassium bicarbonate/citric acid) [prescribing information]. St. Louis, MO: Nomax Inc; April 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/Nomax.2/pubmed" id="Nomax.2" target="_blank">Nomax.2</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IMP.1">
<a name="IMP.1"></a>Institute of Medicine Panel on Dietary Reference Intakes for Electrolytes and Water: Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. http://nationalacademies.org/hmd/reports/2004/dietary-reference-intakes-water-potassium-sodium-chloride-and-sulfate.aspx. Accessed April 6, 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/IMP.1/pubmed" id="IMP.1" target="_blank">IMP.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Upsher-Smith.1">
<a name="Upsher-Smith.1"></a>Klor-Con/EF (potassium bicarbonate effervescent) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; June 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/Upsher-Smith.1/pubmed" id="Upsher-Smith.1" target="_blank">Upsher-Smith.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16085929">
<a name="16085929"></a>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005;62(16):1663-1682. doi:10.2146/ajhp040300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/16085929/pubmed" id="16085929" target="_blank">16085929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Clinical manifestations and treatment of hypokalemia in adults. Sterns RH, Emmett M, Forman JP, eds. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 4, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/Mount.1/pubmed" id="Mount.1" target="_blank">Mount.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-bicarbonate-and-potassium-citrate-effervescent-drug-information/abstract-text/manu.1/pubmed" id="manu.1" target="_blank">manu.1</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9794 Version 198.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
